Bain acquires Olympus life sciences unit for $3.1B
The company aims to expand its position as a workflow solution provider in life science and industrial markets.
Bain acquires Olympus life sciences unit for $3.1B Read More »
The company aims to expand its position as a workflow solution provider in life science and industrial markets.
Bain acquires Olympus life sciences unit for $3.1B Read More »
The new company, called Mozarc Medical, will focus on kidney care technology including home dialysis.
Medtronic, DaVita launch kidney care joint venture Read More »
Although the go-broke date for a pivotal trust fund that props up Medicare was extended by three years, stakeholders urge that action is needed in Washington to address Medicare’s long-term solvency.
The Justice Department on Friday filed to appeal a Thursday ruling by a Texas judge striking down part of the ACA that requires health plans to fully cover certain preventive medical services like HIV and cancer screenings.
Biden administration announces appeal to ACA preventive mandate ruling Read More »
Driving the rate hike is the agency’s decision to phase in the technical risk adjustment changes over three years.
Tidepool Loop, an automated insulin dosing app based on one developed by the DIY diabetes community, received FDA clearance in January.
Grassroots innovation: How a patient-driven device for diabetes won FDA clearance Read More »
Tanto en física como en química, la escala mesoscópica se refiere a la escala de longitud en la que se puede estudiar las propiedades de un material o fenómeno, sin tener que discutir el comportamiento de los átomos individuales. En una modelización mesosc&o …
Predecir la flexibilidad de movimiento del ADN a nivel molecular Read More »
In a potential leap forward for sickle cell disease, Vertex moved closer to launching its one-time treatment for sickle cell disease and transfusion-dependent beta-thalassemia.
Vertex and CRISPR Advance First-In-Kind Therapeutic for SCD Read More »
BioNTech will pay Shanghai-based Duality Biologics $170 million upfront for rights to two of its topoisomerase-1 inhibitor-based antibody drug conjugates.
BioNTech Adds Two ADCs in Second Deal in as Many Months Read More »
Almost two years after its launch, eye-focused gene therapy start-up Vedere Bio II is closing its doors, company leaders announced through a LinkedIn post over the weekend.
Vedere Bio II Closes Doors After Preclinical Studies Fall Short Read More »